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Cryptococcus neoformans is the most common cause of laboratory-
confirmed meningitis in South Africa.1 Despite the increased coverage of 
antiretroviral treatment (ART), the country’s incidence of cryptococcal 
meningitis remains high, and in routine care settings, the disease has a 
case-fatality ratio of >50% at 12 weeks post-diagnosis.2-4 Screening and 
pre-emptive antifungal treatment is desirable to prevent the development of 
cryptococcal meningitis and associated deaths.5-7 
Implementing a high-throughput screening programme has been 
simplified by the development of a sensitive and specific lateral flow 
assay (LFA) (Immuno-Mycologics, Norman, OK, USA) designed to 
rapidly detect cryptococcal antigen (CrAg) in several body fluids.8,9 
In its Rapid Advice guidelines, the World Health Organization 
(WHO) indicates that, before initiating ART in populations with a 
high prevalence of cryptococcal antigenaemia, routine screening for 
cryptococcal disease may be considered among ART-naïve adults 
who have a CD4+ T-lymphocyte count <100 cells/µl.10 In two South 
African ART cohorts, the prevalence of incident antigenaemia among 
patients with a CD4+ T-lymphocyte count <100 cells/µl was 4% and 
7% respectively.11,12 This is greater than the breakpoint above which 
screening was found to be potentially cost-saving in a Ugandan study.13,14 
To reduce disability and deaths associated with HIV infection, 
it has been suggested that laboratory-based screening and pre-
emptive antifungal treatment of cryptococcal disease be routinely 
implemented as part of the South African National Strategic Plan 
for HIV, STIs and TB, 2012-2016.15 This initiative also complements 
government’s efforts to prioritise primary health care (PHC), with a 
shift towards early detection of cryptococcal disease at PHC clinics 
rather than delayed diagnosis of cryptococcal meningitis at hospital 
level. The National Department of Health has recommended phasing 
in cryptococcal screening to the provincial departments (Dr Yogan 
Pillay, personal communication). 
Phased laboratory-based 
implementation 
In the first phase of the programme, lab-based screening will begin 
at almost 500 health facilities in Gauteng and the Free State, served 
by three National Health Laboratory Service (NHLS) laboratories 
performing CD4+ T-lymphocyte testing. In a lab-based strategy, 
NHLS laboratories will reflexively test the remnant specimen of any 
blood sample with CD4+ T-lymphocyte count <100 cells/µl for CrAg 
using the LFA. Results will be reported to the clinician, together 
with CD4+ T-lymphocyte count results, using existing paper and 
electronic methods. 
A phased approach will establish the feasibility and appropriate 
workflow in these labs. This strategy was selected over point-of-care 
(POC) testing for several reasons. 
• First, over 400 000 specimens submitted for CD4+ T-lymphocyte 
testing to 62 NHLS laboratories nationwide in 2011 had a CD4+ 
T-lymphocyte count <100 cells/µl – i.e. 11% of all submitted 
specimens (Professor Wendy Stevens, personal communication). 
In this context, rapidly scaling up implementation beyond the 
first phase is more feasible with a lab-driven strategy. 
• Second, with reflex testing, additional venepuncture would 
be unnecessary and healthcare providers would not need 
to remember to order the test on patients with a CD4+ 
T-lymphocyte count <100 cells/µl. This simplifies the screen-
and-treat algorithm. 
• Third, unless a POC CD4+ T-lymphocyte test is also offered 
at a health facility, a POC LFA would only be done at a follow-
up visit when the laboratory CD4+ T-lymphocyte test result is 
available. This offers no advantage in terms of turn-around time. 
POC CD4+ T-lymphocyte testing is currently available at only a 
few health facilities in South Africa (Professor Wendy Stevens, 
personal communication). In the future, if the LFA is validated 
on whole blood or urine, it could be used as a POC test. 
Training and clinical management 
Healthcare and lab workers must be trained as the screening 
programme is implemented. Training healthcare workers is 
particularly important because the lab-based screening is not 
provider-initiated. Training will consist of a half-day, module-based 
workshop focused on case studies and followed by in-service training 
and mentoring. 
There is currently no standard treatment practice for patients with 
no symptoms and signs of meningitis who screen positive for CrAg. 
Current evidence has been used to inform the clinical treatment 
algorithm for this programme (Fig. 1).10,16,17 For patients testing 
CrAg-positive, clinicians will first evaluate patients for symptoms 
and signs of meningitis (including headache for longer than 24 hours, 
fever, confusion or reduced level of consciousness, blurred vision, or 
neck stiffness). The clinician will also evaluate patients for any special 
situations (previous history of cryptococcal meningitis, pregnancy, 
liver disease, nevirapine use and age <18 years). 
Patients with symptoms or signs of meningitis will be started 
immediately on oral fluconazole (400 mg once daily) and have a 
lumbar puncture performed, or be transferred urgently to a facility 
where a lumbar puncture can be performed, to exclude cryptococcal 
meningitis through cerebrospinal fluid (CSF) analysis. Patients 
with a positive lumbar puncture for cryptococcal meningitis will be 
treated according to South African cryptococcal disease guidelines 
(amphotericin B-based induction treatment for 2 weeks, followed 
by fluconazole 400 mg daily for 8 weeks, followed by secondary 
prophylaxis, 200 mg until the CD4+ T-lymphocyte count >200 cells/
µl for six months on ART).17,18 For patients without symptoms of 
meningitis or symptomatic patients with a negative lumbar puncture, 
treatment with fluconazole (400 mg for 8 weeks and then 200 mg 
until CD4+ T-lymphocyte count >200 cells/µl for 6 months on ART) 
is recommended. 
Note that the WHO Rapid Advice guidelines recommend an 
800 mg daily initial dose of fluconazole. The relatively low dose of 
400 mg daily was only selected because fluconazole is not currently 
available at the higher dose at PHC facilities. The algorithm may be 
revised if evidence suggests that a higher dose is more efficacious 
for asymptomatic antigenaemia or reduces duration of treatment.10,18 
Patients without symptoms of meningitis may also be offered a 
lumbar puncture if it can be performed at the health facility where 
the patient was diagnosed or if they can be rapidly referred to a 
facility that offers it. If lumbar puncture is positive for cryptococcal 
meningitis in asymptomatic patients, the patient should be treated as 
described above. For CrAg-positive patients, ART will be started two 
weeks after antifungal therapy is initiated.10 However, ART initiation 
may need to be delayed to 4 weeks after diagnosis among patients 
with confirmed cryptococcal meningitis (Professor Graeme Meintjes, 
personal communication). 
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Fig. 1. Clinical treatment algorithm for the South African cryptococcal screening programme.
Recommendations (Note: This algorithm may be modified as new evidence is published.) 
• Patients on TB medications. Anti-TB drugs (including INH) and fluconazole can be started at the same time. Because both fluconazole and TB medications 
are potentially hepatotoxic, these patients should preferably be started on an efavirenz-based ART regimen. Patients should be monitored closely for signs of liver 
damage including right upper quadrant abdominal pain, nausea/vomiting, or jaundice. If there are signs of toxicity, then liver function tests should be ordered. 
• Patients on nevirapine. For patients starting ART, an efavirenz-based regimen is preferable to nevirapine, since nevirapine might increase the risk of liver 
damage. If patient is already on nevirapine, then the patient should be monitored closely for signs of liver damage including right upper quadrant abdominal 
pain, nausea/vomiting, or jaundice. If there are signs of toxicity, then liver function tests should be ordered. 
• Patients with previous history of cryptococcal meningitis. Patients with a previous history do not need to be routinely screened. However, patients who 
have new symptoms of meningitis will need to be evaluated for relapse disease and/or immune reconstitution inflammatory syndrome (IRIS). If the patient 
does not have new symptoms, the healthcare provider should ensure that the patient has received or is receiving adequate maintenance therapy (fluconazole 
200 mg until CD4+ T-cell count >200 cells/µl on ART and for a minimum of 12 months total) after being treated with induction and consolidation therapy. 
• Pregnancy or breastfeeding mothers. Because fluconazole can be harmful to a fetus, all women of childbearing age should have a pregnancy test. The risks, 
benefits and alternatives to fluconazole treatment should be discussed with the patient. Consultation with a physician experienced in the care of HIV-infected 
patients is recommended. Breastfeeding mothers also require consultation with an experienced physician as fluconazole can be transmitted through breast 
milk to the infant. Women of childbearing age who are not yet pregnant and are starting fluconazole treatment should be advised to avoid becoming pregnant 
during treatment. 
• Liver disease. Patients with history of liver disease (cirrhosis, hepatitis, etc.), jaundice, or abnormal liver enzyme tests (more than twice upper limit of 
normal) require careful monitoring because fluconazole may cause liver damage. Consultation with a physician experienced in the care of HIV/AIDS patients 
is recommended. 
• Children. Screening is not recommended for children as cryptococcal meningitis is less common in this group. All children who are CrAg-positive should be 
referred for lumbar puncture (LP). Children with a positive LP should be managed according to the national guidelines: amphotericin B 1 mg/kg/dose IV for at 
least 2 weeks, followed by fluconazole 12 - 15 mg/kg daily for 8 weeks, followed by fluconazole 6 - 10 mg/kg daily for life or until the CD4% >25% (if 2 - 6 years 
old) or CD4+ T-lymphocyte count >200 cells/µl (if >6 years old); children aged <2 years should be continued on treatment for life.  Children with a negative 
LP should be treated with a weight-based fluconazole regimen of 12 - 15 mg/kg daily for 8 weeks, followed by 6 - 10 mg/kg daily until the CD4% >25% (if ≤6 
years old) or CD4+ T-lymphocyte count >200 cells/µl (if >6 years old). Daily fluconazole dose for children should never exceed 400 mg. 
• ART initiation. ART may need to be delayed to 4 weeks after diangnosis in patients with confirmed cryptococcal meningitis.
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A data safety monitoring committee, consisting of South African 
clinicians who are experts in the field of HIV management, will 
convene to regularly review the treatment algorithm, any reported 
adverse events and programme indicator data.
Monitoring and evaluation 
The primary goal of cryptococcal screening is to reduce morbidity 
and mortality associated with cryptococcal meningitis in South 
Africa. Initially, screening may increase the number of incident cases 
of cryptococcal disease, and improved detection may increase the 
number of cases of meningitis. However, these are expected to plateau 
as national screening is implemented and coverage is expanded. 
Incidence of cryptococcal disease and the in-hospital case-
fatality ratio will be monitored by the national Group for Enteric, 
Respiratory, and Meningeal Surveillance-South Africa (GERMS-
SA) surveillance programme.4 The programme’s impact on 
overall mortality reduction will be assessed by comparing 6- and 
12-month mortality among HIV-infected patients who are newly 
initiated on ART before and after implementing cryptococcal 
screening at selected participating clinics. This process will be 
facilitated by the routine electronic capture of ART programme 
data, including outcome data, on TIER.net (Dr Meg Osler, personal 
communication). Laboratory and clinical indicator data, collected 
as part of the screening programme, will be used to perform a 
cost-effectiveness analysis, including costs of screening per patient 
and outcome stratified by treatment. The aim is to demonstrate 
that screening and treating patients with early cryptococcal disease 
(asymptomatic antigenaemia and early cryptococcal meningitis) 
is more cost-effective than treating patients with cryptococcal 
meningitis who are diagnosed only when symptomatic. 
Operational challenges 
Several operational challenges must be addressed as screening is 
implemented. First, cryptococcal screening must be integrated into 
routine management algorithms for patients who require rapid 
ART initiation and may also have TB. Second, for the programme 
to work, patients found to have cryptococcal antigenaemia must be 
immediately traced, assessed and initiated on antifungal treatment 
before they develop meningitis or die. Laboratory reporting and clinic 
tracing systems need to be enhanced. Third, supply, procurement and 
distribution of antifungal drugs to clinic level must be adequate and 
consistent, and nurses who identify patients with antigenaemia need 
to be able to initiate antifungal treatment. The broader issues of data 
collection for programme monitoring and evaluation, integration 
of vertical programmes, patient follow-up and drug supply are not 
specific to the cryptococcal screening programme. 
The National Department of Health has recommended phasing in 
screening to provinces, and the Western Cape provincial government 
has already updated its ART programme guidelines to include 
cryptococcal screening (Professor Graeme Meintjes, personal 
communication). Screening should be prioritised across the country 
because the South African cryptococcal screening programme can 
significantly mitigate the burden and death rate associated with this 
common and deadly fungal opportunistic infection. 
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